广告
药物开发
药理学
医学
计算机科学
风险分析(工程)
药品
计算生物学
生物
作者
Michelle Hemkens,Katie Stamp,Lise I. Loberg,Kévin Moreau,T K Hart
标识
DOI:10.1016/j.drudis.2023.103643
摘要
Targeted protein degraders (TPDs), which act through the ubiquitin proteasome system (UPS), are one of the newest small-molecule drug modalities. Since the initiation of the first clinical trial in 2019, investigating the use of ARV-110 in patients with cancer, the field has rapidly expanded. Recently, some theoretical absorption, distribution, metabolism, and excretion (ADME) and safety challenges have been posed for the modality. Using these theoretical concerns as a framework, the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) Protein Degrader Working Group (WG) conducted two surveys to benchmark current preclinical practices for TPDs. Conceptually, the safety assessment of TPDs is the same as for standard small molecules; however, the techniques used, assay conditions/study endpoints, and timing of assessments might need to be modified to address differences in mode of action of the class.
科研通智能强力驱动
Strongly Powered by AbleSci AI